DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ciraparantag
Ciraparantag
Reversal of Oral Anticoagulation in Patients with Acute Intracerebral Hemorrhage Joji B
Management of Bleeding with Non–Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents
Role of Ciraparantag, Andexanet Alfa, and Idarucizumab
Single-Dose Ciraparantag Safely and Completely Reverses Anticoagulant Effects of Edoxaban
Ciraparantag; Expectations Regarding the U.S
Heparin-Binding Copolymer As a Complete Antidote for Low-Molecular-Weight Heparins in Rats
AMAG Pharmaceuticals, Inc. All© Rights 2019 Reserved AMAG Pharmaceuticals, Inc
Factor Deficiency, As the Aptt Prolongation from These Conditions Will Mask the Effect of Dabigatran on the Aptt
Reversal Agents for Non‐Vitamin K Oral Anticoagulants: Practice Revolution?
Improving Adult Immunization Across the Continuum of Care: Making the Most of Opportunities in the Ambulatory Care
Direct Oral Anticoagulant Reversal: How, When and Issues Faced М Mikhail S
International Nonproprietary Names for Pharmaceutical Substances (INN)
Clinical Controversies in DOAC Reversal
Reversal of Non-Vitamin K Antagonist Oral Anticoagulants (Noacs) in the Presence of Major
Vitamin K Antagonist – Interferes with Cyclic Interconversion of Vitamin K
Pharmacological Profile of Non-Vitamin K Antagonist Oral Anticoagulants
Alternatives to Protamine for Reversal of Unfractionated Heparin (UFH)
Non-Vitamin K Antagonist Oral Anticoagulants (Noacs) Apixaban (Eliquis®), Edoxaban (Lixiana®▼), Rivaroxaban (Xarelto®▼), Dabigatran (Pradaxa®)
Top View
Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update
From Pharmacology to Clinical Practice Riccardo Proietti Ahmed Alturki Nicola Ferri Vincenzo Russo T
Indications and Methods of Anticoagulation Reversal
Antidotes for Reversal of Direct Oral Anticoagulants
DOAC Management: Reversal Options with Case Study Discussion
Novel Oral Anticoagulants and Reversal Agents: Considerations for Clinical Development Troy C
Clinical Controversies in DOAC Reversal
AMAG Pharmaceuticals, Inc. All© Rights 2019 Reservedamag Pharmaceuticals, Inc
Take It Back: Management of Direct Oral Mid-Winter Conference 2/7/2019 Anticoagulants and Reversal Agents
Pulmonary Embolism: Contemporary Medical Management and Future Perspectives
Ciraparantag
Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting
Current Status of Oral Anticoagulant Reversal Strategies: a Review
NOAC Antidotes Who Were Taking Rivaroxaban Or Apixaban, Respectively
Direct Oral Anticoagulants a Discussion Guide
Ondexxya, INN-Andexanet Alfa
Datasheet Inhibitors / Agonists / Screening Libraries a DRUG SCREENING EXPERT
DOAC Reversal JUN2019 Draft
Ciraparantag
The Reversal of Anticoagulation in Clinical Practice
Ciraparantag for Haemorrhage in Patients Receiving New Oral Anticoagulants